44,229 Shares in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) during the third quarter, HoldingsChannel reports. The fund bought 44,229 shares of the company’s stock, valued at approximately $1,105,000.

Other institutional investors also recently modified their holdings of the company. Essex Investment Management Co. LLC grew its position in Kiniksa Pharmaceuticals by 0.4% during the 3rd quarter. Essex Investment Management Co. LLC now owns 200,516 shares of the company’s stock worth $5,011,000 after acquiring an additional 717 shares during the last quarter. CWM LLC increased its position in Kiniksa Pharmaceuticals by 443.0% in the 3rd quarter. CWM LLC now owns 2,449 shares of the company’s stock valued at $61,000 after acquiring an additional 1,998 shares during the period. Bank of New York Mellon Corp increased its position in Kiniksa Pharmaceuticals by 2.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 115,143 shares of the company’s stock valued at $2,150,000 after acquiring an additional 2,563 shares during the period. China Universal Asset Management Co. Ltd. raised its stake in shares of Kiniksa Pharmaceuticals by 65.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 7,810 shares of the company’s stock valued at $195,000 after acquiring an additional 3,076 shares during the last quarter. Finally, Peregrine Capital Management LLC lifted its holdings in shares of Kiniksa Pharmaceuticals by 1.3% during the second quarter. Peregrine Capital Management LLC now owns 239,156 shares of the company’s stock worth $4,465,000 after purchasing an additional 3,111 shares during the period. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the company. JPMorgan Chase & Co. increased their price objective on Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the company an “overweight” rating in a report on Tuesday, November 5th. Jefferies Financial Group started coverage on shares of Kiniksa Pharmaceuticals in a research note on Friday, September 13th. They issued a “buy” rating and a $40.00 price objective on the stock. Finally, Evercore ISI lifted their target price on shares of Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $36.60.

Kiniksa Pharmaceuticals Stock Performance

Shares of KNSA opened at $20.06 on Thursday. The firm has a market cap of $1.45 billion, a PE ratio of -143.28 and a beta of 0.27. Kiniksa Pharmaceuticals, Ltd. has a 52-week low of $16.56 and a 52-week high of $28.15. The business’s 50 day moving average price is $23.01 and its two-hundred day moving average price is $23.11.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last announced its quarterly earnings data on Tuesday, October 29th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.17). The company had revenue of $112.21 million for the quarter, compared to analyst estimates of $111.51 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. Kiniksa Pharmaceuticals’s revenue for the quarter was up 67.4% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.20) EPS. Research analysts predict that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current fiscal year.

Insider Buying and Selling

In other Kiniksa Pharmaceuticals news, CFO Mark Ragosa sold 8,969 shares of the company’s stock in a transaction on Tuesday, December 3rd. The shares were sold at an average price of $21.45, for a total transaction of $192,385.05. Following the transaction, the chief financial officer now owns 22,958 shares in the company, valued at approximately $492,449.10. This represents a 28.09 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, COO Eben Tessari sold 17,000 shares of the firm’s stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $26.87, for a total transaction of $456,790.00. Following the completion of the transaction, the chief operating officer now directly owns 109,975 shares in the company, valued at $2,955,028.25. This trade represents a 13.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 44,592 shares of company stock valued at $1,110,364. 54.57% of the stock is owned by company insiders.

Kiniksa Pharmaceuticals Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.